Eli Lilly & Co.’s stock price declined sharply after a study revealed disappointing results for its experimental weight-loss pill, Orforglipron.

Eli Lilly & Co. reported a first-quarter earnings miss, sending its stock plummeting, amidst intense competition and strategic challenges in the weight-loss drug market.